DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study

Inclusion criteria (abridged) * Male and female subjects with migraine with or without aura fulfilling the diagnostic criteria of the International Classification of Headache Disorders * 3 to 6 migraine attacks per month * Concomitant prophylactic migraine treatment with a beta-blocker or amitriptyline that has been stable in the proceeding 3 months. No changes in this concomitant treatment will be allowed until the end of study follow-up. Exclusion criteria (abridged)Chronic migraine (\>15 days of migraine/ month). * Migraine complicated by medication-overuse headache. * Allergy or hypersensitivity to valproic acid, valproate sodium, or soy. * Known contraindications to valproic acid. * Pregnancy. * Breastfeeding female subjects. * Subjects with significant hepatic dysfunction indicated by SGOT or SGPT \>3 times the upper limit of normal at screening. * Renal impairment indicated by serum creatinine \>1.5mg/dL at screening. * Potentially fertile and sexually active women who do not practice reliable contraception. * Men who do not practice reliable barrier contraception. * Concomitant use of antipsychotic, antidepressant or antiepileptic therapy - with the exception of amitriptyline - within 1 month of screening, or a medical condition that is likely to require such treatment during the trial participation. * An active central nervous system disease deemed to be unstable or progressive during the course of the study that may confound the interpretation of the study results. * Any medical disorder that may makes the subject unlikely to fully complete the study- Blood coagulation disorder. * Concomitant drugs known to interact with VPA.- Alcohol or other drugs abuse. * Therapy with another investigational product within 30 days prior start of study. * Concomitant participation in another trial or study